MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.